| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
We performed analysis of samples from the clinical trail patients administrated TCR(T cell receptor)-gene transduced lymphocytes and researched on adoptive cell therapy of tumor-specific lymphocytes using mouse model. In the clinical trail patients, TCR-transduced lymphocytes were detected in their peripheral blood as approximately 1% of PBMC. The infused cells have been in vivo persisted in all patients as long as 10 months. In the adoptive cell therapy model of TCR transgenic mouse, presence of CD4+ T cells or integrin signals is elevated CD8+ T cell multifunctionality, and enhanced anti-tumor effect. Furthermore, we have almost established mouse model of the adoptive transfer of TCR-gene transduced lymphocytes.
|
